# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Louis Chen reiterates Perspective Therapeutics (AMEX:CATX) with a Overweight.
Cantor Fitzgerald analyst Louis Chen reiterates Perspective Therapeutics (AMEX:CATX) with a Overweight.
Oppenheimer analyst Jeff Jones reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform, Adjusts Target to $19 from $...
Oppenheimer analyst Jeff Jones reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform, Adjusts Target to $19 from $2...
Cantor Fitzgerald analyst Louis Chen reiterates Perspective Therapeutics (AMEX:CATX) with a Overweight.
RBC Capital analyst Gregory Renza reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $3 price t...